Announcements Trials
Browse Landscape

Phase

Phase 1 148Phase 1/2 15Phase 2 4

Status

Recruiting 4Completed 4Unknown 3Terminated 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 4

Conditions

Breast Neoplasms 1277Carcinoma, Non-Small-Cell Lung 926Prostatic Neoplasms 729Neoplasms 632Multiple Myeloma 553Lymphoma 539Colorectal Neoplasms 529Lung Neoplasms 515Leukemia 497Leukemia, Myeloid, Acute 472Neoplasm Metastasis 470Melanoma 425Lymphoma, Non-Hodgkin 417Ovarian Neoplasms 416Leukemia, Lymphocytic, Chronic, B-Cell 386Pancreatic Neoplasms 373Recurrence 335Precursor Cell Lymphoblastic Leukemia-Lymphoma 327Head and Neck Neoplasms 306Lymphoma, Large B-Cell, Diffuse 294Glioblastoma 294Myelodysplastic Syndromes 287Brain Neoplasms 287Lymphoma, Follicular 286Stomach Neoplasms 280Carcinoma, Renal Cell 268Hodgkin Disease 261Carcinoma, Hepatocellular 261Rectal Neoplasms 256Sarcoma 250

Interventions

toripalimab 1tislelizumab 1surufatinib 1Paclitaxel 1PM 01183 1HMPL-013 1Erlotinib Hydrochloride 1Dexamethasone 1Calcium Dobesilate 1Bortezomib 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Completed × Advanced Solid Tumors × Clear all
NCT04716634 2025-03-25

Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors

BeiGene

Phase 2 Completed
84 enrolled 17 charts
Other solid neoplasm

Advanced Solid Tumors

NCT02057380 2024-11-20

A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

Astellas Pharma Inc

Phase 2 Completed
13 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT02454972 2023-03-02

Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors

PharmaMar

Phase 2 Completed
345 enrolled 34 charts 1 FDA
Other solid neoplasm

Advanced Solid Tumors

NCT04169672 2023-03-02

Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors

Hutchmed

Phase 2 Completed
248 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡